INTRODUCTION
The identification and characterization of virus neutralization inducing (VNI) antigenic sites on the glycoproteins of HIV-1 have been the focus of many studies (for review see [1] ). For practical reasons. HIV-I strains and primary HIV-I isolates which efficiently replicate in T cells have predominantly been used to study virus neutralization [1] . In this context it is important to note that macrophage-tropic non-syncytiuminducing (NSI) variants with low efficiency of replication in T cells predominate in the asymptomatic stage and T cell linetropic syncytium inducing (Sl) variants are almost exclusively found in late stages of the infection [2, 3] . The macrophagetropic NSI strains have been shown to exhibit a relatively high level of conservation in their VNI V3 loop [4] . It has been suggested that escape from virus neutralizing (VN) antibodies is based on the relatively high mutation rate generally t Current address: BPRC. Unge Kleiweg 151, 2288 GJ Rijswijk, The Netherlands.
J: Current address: Regional Primate Research Center. 1-421 Health Sciences Center SJ-50, University of Washington, Seattle WA 98195, USA. observed in the virus envelope glycoprotein. Given the fact that also the CD4 binding domain (bd) is relatively conserved, another mechanism of escape from VN antibodies may be postulated for the relative success of NSI/macrophagetropic viruses to persist in the host. To study the basis of this apparent paradox, we have used an env complementation assay in which the biological activities could be compared of human HIV-l-specific monoclonal and potyclonal antibody preparations towards identical HIV-1 strains only differing in their glycoproteins which displayed an SI or an NSI phenotype.
MATERIALS AND METHODS
Human anrihadies, sCD4 and HIV-I envelope glycaproteins. The human monoclonal antibodies (HuMoAbs) used are directed against the CD4 binding domain (GP13 and GP68 [5] ). a highly conserved conformational epitope on gp4l {K14 [6] ) and the HIV-I gpl20 V3 loop (257-D [7] ). Furthermore sCD4 (kindly provided by Dr I. Jones through the MRC AIDS directed programme) and HIVIG |8]) (kindly provided by Dr H. Schuiiemaker) were used as VN agents. The env genes used 116.1 (SI), 16 
.2 (SI), 16.4 (NSI). MN and IIIB] for
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the production of envelope glycoproteitis in the capture antibody ELISA and for the production of chimeric viruses have previously been characterized and described [9, [10] [11] [12] .
Capture (inlihody ELISA for mea.suremcnt nf relative affinity. The relative affinity of the HuMoAbs used in the present study was determined in a previously described ELISA. In short, ELISA plates (Costar. Cambridge. MA 02140. USA. cat. no. 3590), coated with affinity purified sheep immunoglobulins directed against the carboxy terminus of gpl20 (Aalto BioReagents. Dublin. Ireland, cat. no. D7324), were incubated for 2h with cell lysate of recombinant vaccinia virus (rVV) infected HELA [13] cells (16 (NSI) and 16 (SD) or H!V-I infected SupTl [14] cells (MN [11] and IIIB [12] ). Plates were subsequently washed and incubated with serial dilutions of previously described HuMoAbs (GP13. GP68 [5] and 257-D [7] ). The ELISA was completed and read as previously described [10] . The relative amount of antigen bound to the ELISA plates was calibrated by using the same ELISA protocol with serial dilutions of the antigen and a standard excess concentration of polyclonal serum from seropositive individuals. The data presented are the mean values of duplicates in one assay which was performed at least twice with similar results.
Envelope traus-complementution assuy. This assay was based on a previously described n««,v-complementation assay in which an envdefective HIV-l provirus, encoding the bacterial CAT reporter gene [15] . was complemented for a single round of replication by a set of recently described HIV-1 envelope glycoproteins [9] . The env genes encoding these glycoproteins were derived from biologically cloned Sl or NSI viruses, isolated from one single donor (number 16) at a single point in time in natural target cells (peripheral blood mononuclear cells [PBMC] ). in the complementation assay the genes encoding these envelope glycoproteins were co-transfected into a CD4~ cell line (COS [16] ) together with the env-defective molecular clone of the HIV-I IIIB strain. This resulted in the production of virions carrying heterologous envelope glycoproteins which could infect CD4^ cells, like the SupTI cells or PHA stimulated PBMC used in this study. After 3 days cell free supernatants were collected by centrifugation and frozen at -I35''C. For infection the amount of p24 antigen, as determined with a p24 ELISA kit (V5. Organon Teknika. Boxtel. The Netherlands) was calibrated and the level of envelope expression was checked with the capture antibody ELISA (see above). Infection was performed overnight at 37'C in 1ml medium. After 24 h the cells were washed and cultured for 72 h. CAT activity in these cells was measured in a previously described CAT assay using a two-phase extraction system [17] . CAT activities expressed in the cells were considered a direct measure of virus infectivity in these assays.
RESULTS
Relative affinity of HuMoAbs for HIV-I envelope glycoproteins
The HuMoAbs used in these experiments were selected on basis of their epitope specificities and relative affinities in the capture antibody ELISA for different HIV-I envelope glycoproteins ( Table 1 ). The same reeombinant envelope glycoproteins were used in the env complementation assay ( Table  2 ). Both CD4 bd specific HuMoAbs GP13 and GP68 showed an overall higher relative affinity for the glycoproteins of the T eell line adapted HlV-1 strains IIIB atid MN than for the glycoproteins derived from the donor number 16 HIV-1 strains. The V3 loop specific HuMoAb 257-D showed a high relative affinity for the glycoproteins of the MN-like HIV-I strains and no binding was observed in this ELISA with the glycoproteins of HIV-1 IIIB (Table 1) .
Virus neutralization and enhancement of viral infectivity by sCD4 and human antibodies
The VN activities of human antibodies and sCD4 toward T cell line adapted strains HIV-1 MN and HIV-1 IIIB(Tabte2) have been documented previously [10] [11] [12] [13] . The CD4 bd specific HuMoAbs GP13 and GP68 as well as HIVIG and sCD4. inhibited infectivity of HIV-1 16.2 (SI) only to a limited extent (< 50%) when tested at a concentration (l5/(g/ml) that significantly inhibited infectivity of HIV-1 IIIB in the env complementation assay (reduction to 15%, 12%, 9% and 8% respectively) ( Table 2 ). The V3 domain specific HuMoAb tested at the same concentration, neutralized HIV-1 16.2 (SI), as was shown by a reduction of CAT activities to 0.7% (Table 2) . No major biological activity of any of the antibodies tested or sCD4, was observed against HIV-1 16.1 (SI) as was shown by a reduction of CAT activity with 2-9% only, using 15//g/ml antibody ( Table 2 ).
In contrast to the VN activities observed with the SI viruses, the same concentration of ail these VN antibodies and sCD4 caused a dramatic enhancement of infectivity of HIV-1 16.4 which has a NSI envelope (> six-fold increase in CAT activity) ( Table 2) . In order to demonstrate the dose dependency of these phenomena, dose response curves were made with the V3 domain specific HuMoAb 257-D, which exhibited the highest affinity for all the envelop proteins (Fig. I ). When these experiments were repeated in PHA stimulated PBMC essentially the same phenomena were observed. The overall differences were however less pronounced in this system (average enhancement about 50%) probably due to a limited cellular host range of this virus (A. C. Andeweg et al, unpublished observations).
DISCUSSION
Using an assay that is highly sensitive for measuring viral entry we have shown in the present study that both sCD4 and human antibodies which neutralize SI HIV-1 strains may enhance infectivity of NSI HIV-1 strains. HIVIG, sCD4 and the CD4 bd specific HuMoAbs GPI3 and GP68 readily neutralized the HIV-1 IIIB strain whereas limited or no VN activity was observed against the primary HIV-I strains from donor number 16. This supports previous observations that sCD4, CD4 bd specific HuMoAbs and HIVIG have little or no neutralizing activity against primary virus strains (M. Schutten. personal observation and [18] ). It has been shown by several groups that VN capacity of V3 loop specific MoAbs toward T cell line adapted HIV-1 strains is dependent on the affinity of the antibody for the V3 loop of the HIV-1 strain used [7, 19] . However, in the present study we showed that VN activity of V3 loop specific HuMoAb 257-D toward the SI HIV-1 strains from donor number 16 is not directly related to its relative affinity for the glycoproteins involved: identical relative affinities for the 16.1 (SI) and 16.2 (SI) envelope glycoproteins were observed, but reductions in the env complementation assay proved to be 9 and 99.3% respectively. This was unexpected since both envelopes exhibit SI capacity and a 95% overall predicted amino acid sequence homology exists between these envelopes [9] . Since we have previously shown that other domains than the V3 domain are involved in membrane fusion [10] . it may be speculated that HIV-1 16.1 is less dependent on the V3 domain to establish membrane fusion and infection.
The efficiency of entry into T cell lines of the NS! HIV-1 strain 16.4 was significantly lower than that of the SI HIV-1 strains 16.1 and 16.2 as shown by a > six-fold lower CAT activity. The infectivity of the NSI HIV-I strain was however enhanced to levels comparable to those of the SI HlV-1 strains by the administration of sCD4 or antibodies that neutralized these SI HlV-1 strains. Different mechanisms for HIV-1 specific antibody mediated enhancement have been described, including Fc receptor-and complementmediated enhancement [20, 21] . Two observations argue against the same mechanism in our experiments. Firstly, SupTl cells do not express Fc receptors [14] and complement was not present in the assays. Secondly, enhancement of HIV-I 16.4 (NSI) was also observed with sCD4 (Table 2 ). An explanation for the observed enhancement can be found in a mechanism previously described for the enhancement of noncytopathic SIV agm infectivity and induction of HIV-2 mediated cell fusion of CD4' cells, by sCD4. In these systems sCD4 does not induce dissociation of surface glycoprotein (SU) from infected cells [22, 23] . In contrast, sCD4 does induce dissociation of SU from cells infected with T cell line adapted HIV-l strains which are readily neutralized by sCD4 [24] . We hypothesize that both sCD4 and the antibodies we studied, cause conformational changes in the viral envelope complex of certain NSI/macrophage-tropic HIV-l strains exposing cryptic fusion sites as was also shown in the SlVagm and HIV-2 systems [22, 23] . These changes would allow a more efficient virus-cell fusion that is less dependent on the presence of CD4 on the target cell membrane. Taken together our data suggest that naturally occurring antibodies to the so-called HIV-l VNI antigenic sites, may cause either neutralization or enhancement dependent on the biological phenotype of the virus recognized. If indeed our findings are a reflection of a more general phenomenon of enhancement also found in infections with other lentiviruses like HlV-2 (23] and SIVagm [22] , they may explain why early after HIV-l infection predominantly viruses with an NSI/ macrophage-tropic phenotype are found and why these viruses are able to persist in the infected host despite the conserved nature of their 'VNI' antigenic sites. The observed enhancement would actually favour replication of viruses displaying the NSI/macrophage-tropic phenotype, whereas viruses displaying the SI/T cell line-tropic phenotype are neutralized.
These observations may not only have implications for our understanding of the pathogenesis of HIV-l infection but also for the development of immunization strategies. If this observation is the reflection of a more general phenomenon, the induction or administration of antibodies that neutralize viruses of the SI/T cell-tropic phenotype, which is a commonly followed strategy at present, may actually be counter productive.
